IGC Reports Financial Results for the June 30, 2021, Quarter

Rhea-AI Summary

India Globalization Capital, Inc. (IGC) reported financial results for Q2 2021, revealing revenues of approximately $77,000, down from $584,000 in Q2 2020. The decline is attributed to COVID-19's impact, particularly in its Infrastructure segment. Notably, IGC received a patent for its Alzheimer’s treatment, IGC-AD1, and completed its Phase 1 clinical trial. R&D expenses rose to about $444,000 due to the trial, while the company recorded a net loss of $1.8 million, slightly improved from $1.9 million a year earlier. Liquidity remains adequate for upcoming efficacy trials.

Positive

• Patent granted for IGC-AD1 treatment for Alzheimer's disease.
• Completion of Phase 1 clinical trial for IGC-AD1.
• Other net income increased by 804% due to PPP Note forgiveness.

Negative

• Revenue decreased from $584,000 in Q2 2020 to $77,000 in Q2 2021.
• Net loss of $1.8 million, indicating ongoing financial struggles.

India Globalization Capital, Inc. (NYSE American: IGC) announces its financial results for the three months ended June 30, 2021.

Recent highlights:

• Patent: On July 20, 2021, the United States Patent and Trademark Office (“USPTO”) granted the Company a patent (#11,065,225) for the treatment of Alzheimer’s disease entitled “Ultra-Low dose THC as a potential therapeutic and prophylactic agent for Alzheimer’s Disease.” The original patent application was initiated by the University of South Florida (“USF”) and filed on August 1, 2016. IGC holds an exclusive license agreement with USF with respect to the patent and associated research. The patent relates to IGC’s proprietary formulation, IGC-AD1, intended to assist in the treatment of individuals living with Alzheimer’s disease.
• Phase 1 Clinical Trial: On June 23, 2021, IGC announced the completion of Cohort 3, the final cohort of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals with Alzheimer’s disease. The Company has completed all dose escalation studies associated with the Phase 1 Alzheimer’s trial. We are in the process of compiling safety, tolerability, neuropsychiatric inventory, genotyping, phenotyping, and pharmacokinetics lab data for submission to the U.S. Food and Drug Administration (“FDA”).

Revenue was approximately $77 thousand and $584 thousand for the three months ended June 30, 2021, and the three months ended June 30, 2020, respectively. Revenue in the three months ended June 30, 2021, and June 30, 2020, is primarily derived from our Life Sciences segment, which involves the sale of products such as cannabinol (“CBD”)-infused tinctures, gummies, and lotions. Primarily from closures due to COVID-19, revenue in our Infrastructure segment for the three months ended June 30, 2020, was nil.

Selling, general and administrative expenses for the two quarters in 2021 and 2020 are the same at approximately $1.8 million.

Research and Development expenses are attributed to conducting the Phase 1 Alzheimer’s trial as well as product research in our Life Sciences segment. The R&D expenses for the three months ended June 30, 2021, are approximately $444 thousand and approximately $222 thousand for the three months ended June 30, 2020. The expense in both quarters is mostly associated with the phase 1 Alzheimer’s clinical trial. We expect R&D expenses to increase as we increase staffing to progress to efficacy trials on Alzheimer’s patients using IGC-AD1, subject to FDA.

Other net income increased by approximately $394 thousand or 804% during the three months ended June 30, 2021. The total other income for the three months ended June 30, 2021, and 2020 is approximately $443 thousand and $49 thousand, respectively. The increase is from the forgiveness of a PPP Note that the Company secured during the pandemic.

Net loss for the three months ended June 30, 2021, was approximately $1.8 million or $0.04 per share, compared to approximately $1.9 million or $0.05 per share for the three months ended June 30, 2020.

Regarding Liquidity, the Company anticipates that it has adequate liquidity to carry out the Alzheimer’s related efficacy trials, though the Company expects to opportunistically raise capital as and when it can.

About IGC: IGC operates two lines of business: (i) infrastructure and (ii) life sciences. The Company is based in Potomac, Maryland, U.S.A. Social media: www.igcinc.us / www.igcpharma.com / Twitter @IGCIR

Forward-looking Statements: This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based largely on IGC’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC’s control. For the next several years, our success is highly correlated primarily with the successful outcome of our clinical trials and the recovery of the world and local economies following the COVID-19 pandemic, and, secondarily, on the sale of our products and services candidates. IGC may not be able to complete human trials on our investigational drug candidates, or, once conducted, the results of human trials testing may not be favorable or as anticipated. Our projections and investments anticipate stable pricing, which may not hold out over the next several years, and certain regulatory changes, specifically in states where medical cannabis has been, is, or will be legalized and the diseases which we anticipate our products will target are approved conditions for treatment or usage with cannabis/cannabinoids. We may not be able to protect our intellectual property adequately or receive patents. We may not receive regulatory approval for our products, or trials. An additional risk factor worth highlighting specifically related to patent licensing is that the patent applications we have licensed may not be granted by the USPTO, even if the Company is in full compliance with USPTO requirements. We may not have adequate resources including financial resources, to successfully conduct all requisite clinical trials, to bring a product to market, or to pay applicable maintenance fees over time. We may not be able to successfully commercialize our products even if they are successful and receive regulatory approval. Failure or delay with respect to any of the factors above could have a material adverse effect on our business, future results of operations, our stock price, and our financial condition. Actual results could differ materially from these forward-looking statements as a result of, the factors described both herein and ]in IGC’s SEC filings. IGC incorporates by reference the Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on June 14, 2021, as if fully incorporated and restated herein. In light of these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will in fact occur.

< Financial Tables to Follow>

India Globalization Capital, Inc. CONSOLIDATED BALANCE SHEETS (in thousands, except share data)
		June 30, 2021 ($)				March 31, 2021 ($)
ASSETS
Current assets:
Cash and cash equivalents			13,319				14,548
Accounts receivable, net			162				175
Inventory			5,476				5,478
Non-Marketable securities			-				80
Deposits and advances			3,233				3,236
Total current assets			22,190				23,517
Intangible assets, net			405				407
Property, plant and equipment, net			10,704				10,840
Non-Marketable securities			11				12
Claims and advances			596				603
Operating lease asset			538				488
Total long-term assets			12,254				12,350
Total assets			34,444				35,867
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable			567				476
Accrued liabilities and others			1,542				1,588
Short-term loans			3				304
Total current liabilities			2,112				2,368
Long-term loans			147				276
Other liabilities			15				15
Operating lease liability			433				405
Total non-current liabilities			595				696
Total liabilities			2,707				3,064
Commitments and Contingencies – See Note 12
Stockholders' equity:
Preferred stock, $0.0001 par value: authorized 1,000,000 shares, no shares issued or outstanding as of June 30, 2021 and March 31, 2021.			-				-
Common stock and additional paid-in capital, $0.0001 par value: 150,000,000 shares authorized; 48,284,017 and 47,827,273 shares issued and outstanding as of June 30, 2021 and March 31, 2021, respectively.			110,528				109,720
Accumulated other comprehensive loss			(2,860)				(2,774	)
Accumulated deficit			(75,931)				(74,143	)
Total stockholders' equity			31,737				32,803
Total liabilities and stockholders' equity			34,444				35,867

These financial statements should be read in connection with the accompanying notes on Form 10-Q for the quarter ended June 30, 2021, filed with the SEC on August 11, 2021.

India Globalization Capital, Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except loss per share and share data)

		Three months ended June 30,
		2021   ($)				2020   ($)
Revenue			77				584
Cost of revenue			(51)				(538	)
Gross Profit			26				46
Selling, general and administrative expenses			(1,776)				(1,755	)
Research and development expenses			(444)				(222	)
Operating loss			(2,194)				(1,931	)
Impairment of investment			(37)				-
Other income, net			443				49
Loss before income taxes			(1,788)				(1,882	)
Net loss attributable to common stockholders			(1,788)				(1,882	)
Foreign currency translation adjustments			(86)				(58	)
Comprehensive loss			(1,874)				(1,940	)
Loss per share attributable to common stockholders:
Basic & diluted		$	(0.04)			$	(0.05	)
Weighted-average number of shares used in computing loss per share amounts:			47,910,866				40,189,222

These financial statements should be read in connection with the accompanying notes on Form 10-Q for the quarter ended June 30, 2021, filed with the SEC on August 11, 2021.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005835/en/

FAQ

What were IGC's revenues for the second quarter of 2021?

IGC reported revenues of approximately $77,000 for Q2 2021.

How did IGC perform in terms of net loss for Q2 2021?

IGC recorded a net loss of approximately $1.8 million in Q2 2021.

What is the significance of the patent granted to IGC?

The patent relates to IGC's Alzheimer's treatment, IGC-AD1, which could enhance its market position.

What are the expectations for IGC's R&D expenses moving forward?

R&D expenses are expected to increase as IGC progresses to efficacy trials on Alzheimer’s patients.